Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NYSE: TAK) | Delayed: 20.24 -0.12 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.36 | 52 Week High | $0.55 | |||
| Open | $20.28 | 52 Week Low | $0.55 | |||
| Day High | $20.39 | P/E | N/A | |||
| Day Low | $20.17 | EPS | $-0.20 | |||
| Volume | 1,236,866 | |||||
